Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: NIHR Journals Library 2010-01-01
Seri Bilgileri:Health Technology Assessment
Konular:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
Online Erişim:https://doi.org/10.3310/hta14020
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller